Virus and immune combo takes on deadly brain cancer
NCT ID NCT07472790
First seen Mar 20, 2026 · Last updated Apr 29, 2026 · Updated 4 times
Summary
This early-phase study tests a new treatment for people with recurrent high-grade glioma, a fast-growing brain cancer that has returned after standard therapy. The treatment combines a specially designed virus that targets cancer cells with an immunotherapy drug that helps the immune system attack the tumor. The study will enroll 15 adults to see if this combination can help them live longer and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sanbo Brain Hospital, Capital Medical University
Beijing, Chaoyang District, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.